Landscape Capital Management L.L.C. Has $1.04 Million Stock Holdings in Pfizer Inc. $PFE

Key Points

• Landscape Capital Management L.L.C. increased its position in Pfizer Inc. by 38.7%, acquiring an additional 11,469 shares during the first quarter, bringing its total holdings to 41,077 shares, valued at over $1 million.
• Pfizer recently reported quarterly earnings of $0.78 EPS, surpassing expectations, with revenue reaching $14.65 billion, marking a 10.3% increase from the same period last year.
• The company announced a quarterly dividend of $0.43 per share, with a current dividend yield of 7.0%, indicating a payout ratio of 91.49%.

Landscape Capital Management L.L.C. grew its stake in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 38.7% in the first quarter, according to the company in its most recent filing with the SEC. The firm owned 41,077 shares of the biopharmaceutical company's stock after acquiring an additional 11,469 shares during the quarter. Landscape Capital Management L.L.C.'s holdings in Pfizer were worth $1,041,000 as of its most recent SEC filing.

Other institutional investors have also recently modified their holdings of the company. Clarity Asset Management Inc. bought a new stake in shares of Pfizer during the 4th quarter valued at $27,000. Gould Capital LLC lifted its position in shares of Pfizer by 97.2% during the 4th quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company's stock valued at $27,000 after acquiring an additional 493 shares during the period. GKV Capital Management Co. Inc. bought a new stake in shares of Pfizer during the 1st quarter valued at $27,000. North Capital Inc. bought a new stake in shares of Pfizer during the 1st quarter valued at $28,000. Finally, Bayforest Capital Ltd bought a new stake in shares of Pfizer during the 1st quarter valued at $28,000. 68.36% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of analysts have recently weighed in on PFE shares. HSBC cut their target price on Pfizer from $27.00 to $26.00 and set a "buy" rating for the company in a research report on Monday, May 19th. Jefferies Financial Group boosted their price target on Pfizer from $32.00 to $33.00 and gave the stock a "buy" rating in a report on Wednesday, May 21st. Berenberg Bank lowered their price target on Pfizer from $28.00 to $25.00 and set a "hold" rating for the company in a report on Thursday, May 29th. Citigroup boosted their price target on Pfizer from $25.00 to $26.00 and gave the stock a "neutral" rating in a report on Wednesday, August 6th. Finally, Morgan Stanley boosted their price target on Pfizer from $32.00 to $33.00 and gave the stock an "equal weight" rating in a report on Wednesday, August 6th. Two research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, eleven have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of "Hold" and an average target price of $28.12.

Pfizer Price Performance

PFE traded up $0.14 on Friday, reaching $24.74. The stock had a trading volume of 37,002,549 shares, compared to its average volume of 42,996,172. Pfizer Inc. has a fifty-two week low of $20.92 and a fifty-two week high of $30.43. The firm has a 50-day moving average of $24.79 and a 200-day moving average of $24.37. The company has a current ratio of 1.16, a quick ratio of 0.85 and a debt-to-equity ratio of 0.65. The company has a market capitalization of $140.65 billion, a price-to-earnings ratio of 13.16, a price-to-earnings-growth ratio of 0.88 and a beta of 0.55.

Pfizer (NYSE:PFE - Get Free Report) last issued its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.58 by $0.20. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The business had revenue of $14.65 billion during the quarter, compared to analysts' expectations of $13.43 billion. During the same quarter in the prior year, the firm earned $0.60 EPS. The business's revenue for the quarter was up 10.3% compared to the same quarter last year. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. As a group, sell-side analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 2nd. Shareholders of record on Friday, July 25th will be issued a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 7.0%. The ex-dividend date of this dividend is Friday, July 25th. Pfizer's dividend payout ratio is presently 91.49%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.